Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Convertible Debt (2022 - 2025)

Historic Convertible Debt for ImmunityBio (IBRX) over the last 4 years, with Q3 2025 value amounting to $500.8 million.

  • ImmunityBio's Convertible Debt fell 1482.56% to $500.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $500.8 million, marking a year-over-year decrease of 1482.56%. This contributed to the annual value of $461.9 million for FY2024, which is 1994.52% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Convertible Debt is $500.8 million, which was down 1482.56% from $492.1 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Convertible Debt registered a high of $588.0 million during Q3 2024, and its lowest value of $165.3 million during Q3 2023.
  • Moreover, its 4-year median value for Convertible Debt was $492.1 million (2025), whereas its average is $447.9 million.
  • Over the last 5 years, ImmunityBio's Convertible Debt had its largest YoY gain of 25572.54% in 2024, and its largest YoY loss of 1994.52% in 2024.
  • Quarter analysis of 4 years shows ImmunityBio's Convertible Debt stood at $241.3 million in 2022, then skyrocketed by 139.13% to $577.0 million in 2023, then dropped by 19.95% to $461.9 million in 2024, then grew by 8.43% to $500.8 million in 2025.
  • Its last three reported values are $500.8 million in Q3 2025, $492.1 million for Q2 2025, and $485.7 million during Q1 2025.